Rights and permissions
About this article
Cite this article
Rofecoxib: fewer GI adverse events than nonselective NSAIDs. Inpharma Wkly. 1363, 21 (2002). https://doi.org/10.2165/00128413-200213630-00050
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200213630-00050